GOLDENWELL BIOTECH, INC. (GWLL) Return on equity 2019–2023
GOLDENWELL BIOTECH, INC. (GWLL) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-139.3%FY2023 · since FY2019: -0.9% → -139.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -139.3% | +349.3 pp |
| FY2022 | -488.6% | -449.8 pp |
| FY2021 | -38.8% | -36.2 pp |
| FY2020 | -2.5% | -1.6 pp |
| FY2019 | -0.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More GWLL financial trends
GWLL RevenueGWLL Net incomeGWLL Net marginGWLL Gross profitGWLL Gross marginGWLL Operating incomeGWLL Operating marginGWLL Operating cash flowGWLL Free cash flowGWLL Capital expendituresGWLL Stock buybacksGWLL Dividends paidGWLL Total assetsGWLL Total liabilitiesGWLL Shareholders’ equityGWLL overview →